Pharmaron Acquires State-of-the-Art Biomanufacturing Site in the United Kingdom from AbbVie

Pharmaron Beijing Co., Limited (Stock Code: 300759.SZ/3759.HK) (“Pharmaron”) announced today that it has entered into a definitive agreement to acquire Allergan Biologics Limited (“The ABL site”) in Liverpool, UK, for US$118.7 million in cash from AbbVie. The transaction is expected to close in the second quarter of 2021, subject to the satisfaction of customary closing conditions.

CEO Update | Monday 01 March

If you want to understand how central life sciences entrepreneurialism is to this Government’s economic strategy, then this pre-Budget Facebook video by Boris Johnson makes for interesting viewing.

NovaBiotics announces latest licensing deal

Licensing Deal for NP213 Nail Fungus Treatment is Another Key Milestone for NovaBiotics

Rare Disease Day: A new perspective on quality of life

This year’s Rare Disease Day is a little different. Most years there would be events in Parliament, receptions and press events on Potters Fields near Tower Bridge. However, owing to the ongoing COVID-19 pandemic, none of those events is happening in quite the same way as before.

Coulter Partners announces new appointments in London, the US and Germany

Global Life Sciences executive search specialist, Coulter Partners is delighted to announce continuing growth across the company in 2021. The London team expands with new Associates, Lucy Webb and Ana Delgado, Research Analysts, Jacob Taylor and Liam Fryer, and Director, Carina McEntire. In the US, Ayn Teigman joins as Associate and Irlanda Almendarez as Senior Research Associate. In Frankfurt, the team is strengthened with Sonia Keim, Associate and Katja Färber, Senior Research Associate.

New antibody reagents for Covid Rapid nucleocapsid antigen lateral flow tests

Industry access to UK Academic output for novel antibody pairs to build next generation of tests

Polish expansion for Discovery Park-based science team boosts European connectivity for Kent and UK

A team of Discovery Park scientists researching human neurological and psychiatric health conditions is expanding research opportunities for its Kent-based team in mainland Europe, by opening an additional laboratory in Poland.

CEO Update | Monday 22 February 2021

The Government has announced the creation of the Advanced Research and Invention Agency (ARIA), a new UK research agency that will back high-risk, high-reward projects, set to launch next year. ARIA will be Britain’s answer to the USA’s Defense Advanced Research Projects Agency (DARPA), which has had an incredible impact by funding the best research and innovation wherever it is found, including supporting UK companies in the past.  The search for the Agency’s leadership has now begun and we are seeking to understand how the new entity will be run and operate – any insight from members would be very welcome.

Guest Blog | The Versus Arthritis charity partnership with the Bioindustry Association

Reflecting on our 12 months partnership as Bioindustry Association’s charity of the year.

Fieldfisher Life Sciences sector group advised on £370 million of ECM transactions in 2020

Fieldfisher’s Band 1 ranked equity capital markets team advised on approximately £370 million worth of deals within the life sciences and healthcare sector last year.